{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4JSd6_ELDA","lastupdate":"2022-11-22T00:00:00.000Z","update_date":"2022-11-22T00:00:00.000Z","lastModified":"Jul 2, 2021","active":1,"confidence_score":100,"confidence_score_reason":"","urlname":"everads-therapy","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$1DsWac0keu92mItKvilb2Avyh84BvwB21U59qkHMpgPmJBVeiXrSRn","name":"Everads Therapy","oneliner":"Delivery System for Injectable Therapies into the Eye","registrar":"515541324","website":"https://www.everads-therapy.com/","careerspage":"","founded_month":1,"founded_year":2017,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/17988603","instagram":""},"social":["https://www.linkedin.com/company/17988603"],"flattenedsociallinks":"https://www.linkedin.com/company/17988603","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"1-10","employees_exact":10,"patent":1,"raised":1000000,"stage":"Seed","public_stage":"Seed","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Everads-Therapy","Evarads Therapy","Evarads-Therapy"],"about":"Everads Therapy is an early-stage life sciences company developing retinal treatment delivery technologies. The companys delivery system aims to improve the efficacy and safety of existing and potential drug therapies, with the goal of overcoming significant challenges in current treatment methodologies for retinal and macular diseases.\r\n\r\nEverads Therapy operates within the RAD Biomed incubator in Tel Aviv, Israel. Its underlying technologies have been licensed from the Sheba Medical Center at Tel Hashomer.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97237684943","country":null,"address":{"israeli":[{"id":"de79c9ad-c583-436c-a9ef-965c8080b453","city":"Tel Aviv-Yafo","type":null,"address":"HaBarzel Street 27, Tel Aviv-Yafo, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"R6McAA71BE0AsSJ4dxyx3nNegyV8m1DtueeZYu7rllrEEeSQoggB0M","date":"Jul 30, 2025","link":"https://www.prnewswire.com/il/news-releases/everads-announces-two-oral-presentations-at-asrs-2025-including-full-clinical-trial-results-with-its-novel-suprachoroidal-injector-302517682.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"Everads Therapy","layoffs":null,"summary":"Everads Therapy, a clinical-stage company, has announced promising results from its first-in-human clinical trial and preclinical data at the 2025 American Society of Retina Specialists Annual Meeting. The companys novel suprachoroidal delivery technology, the Everads Injector, demonstrated safety, feasibility, and ease of use for treating retinal diseases, particularly diabetic macular edema and retinal detachment. The technology offers a minimally invasive, office-based treatment option, potentially transforming retinal detachment repair. Everads Therapy, a spin-out from DALI Medical Devices, collaborates with partners across various therapeutic modalities to maximize its delivery platforms potential.","partners":["DALI Medical Devices","RAD Biomed","Sheba Tel Hashomer Medical Center"],"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["clinical trial","retinal diseases","suprachoroidal delivery","retinal detachment","minimally invasive"],"date_of_event":"2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"CaMMdNpwO9VYpIHpOpB48W1NbtoyIKf1QP6o8aigyP0570nIveAS0T","news_summary":"/PRNewswire/ -- Everads Therapy, a clinical-stage company leveraging its novel suprachoroidal delivery technology to advance the treatment of retinal diseases,...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Z7y1kxev0ZFtEXFW4a628trKL0IelUCSGbYBLBpDSz2bxBu4tS2O3g","date":"Sep 19, 2024","link":"https://www.prnewswire.com/il/news-releases/everads-presents-clinical-data-from-first-in-human-trial-of-suprachoroidal-delivery-technology-at-euretina-302252984.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"clinical results","company":"Everads Therapy","layoffs":null,"summary":"Everads Therapy, a clinical-stage biotechnology company, presented promising initial clinical results from a first-in-human study at the 24th EURETINA Congress in Barcelona. The study demonstrated the safety, feasibility, and tolerability of the Everads Injector for delivering drugs to the back of the eye via the suprachoroidal space. These results validate the use of the Injector in a clinical, office-based setting and will support the clinical trial applications of Everads gene therapy license partners. The company is now recruiting patients for the next cohort, with full results expected at an upcoming medical congress. Everads technology aims to improve the efficacy and safety of treatments for retinal diseases through non-surgical delivery methods.","partners":[],"customers":[],"investors":[],"confidence":10,"key_topics":["clinical trial","suprachoroidal delivery","retinal diseases","gene therapy","non-surgical"],"date_of_event":"2023-10-01","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Partners  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"IuIKIoqXB7WpeTvwqOgg3RqLLUcmRFuFgRxDt5PJoSfJyHuNBM6oTi","news_summary":"/PRNewswire/ -- Everads Therapy, a clinical stage biotechnology company developing a platform for non-surgical delivery of therapeutics to the back of the eye...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"fdb0b68e-76c4-4610-88f1-65a4d093cfb5","date":"Jun 30, 2021","link":"https://www.prnewswire.com/news-releases/everads-enters-into-collaboration-to-evaluate-its-suprachoroidal-delivery-technology-with-a-clinical-stage-gene-therapy-company-301323334.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"collaboration, gene therapy, retinal diseases, suprachoroidal delivery","company":"Everads Therapy","layoffs":null,"summary":"Everads Therapy has entered into a collaboration with a clinical-stage gene therapy company to evaluate suprachoroidal delivery for its gene therapy pipeline programs. The collaboration aims to explore the feasibility of using Everads delivery platform to deliver proprietary viral vectors to the choroid and retina. The financial terms of a future license have been agreed upon, including an upfront licensing fee, development-related milestones, and commercial royalties. Everads suprachoroidal delivery system enables safe and effective delivery of therapy to target choroidal and retinal tissues. The companys technology was licensed from the Sheba Medical Center and further developed in collaboration with DALI Medical Devices. Everads Therapy aims to restore vision in patients with retinal diseases through optimal treatment via suprachoroidal delivery.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["suprachoroidal delivery","gene therapy","retinal diseases","collaboration","delivery technology"],"date_of_event":"June 30, 2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"HWgXaMQEiABMRR5osbwCGCMNqfjt9D72KaXIjyuPRowdQUZsQMYA8R","news_summary":"Everads Enters into Collaboration to Evaluate its Suprachoroidal Delivery Technology with a Clinical-Stage Gene Therapy Company","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5ba73eba-d750-49ec-8df5-1d3b8053f3d3","date":"Aug 18, 2020","link":"https://www.prnewswire.com/il/news-releases/global-pharma-company-exercises-rights-for-exclusive-use-of-everads-drug-delivery-technology-in-specific-retinal-targets-301113798.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"collaboration, milestone achievement","company":"Everads Therapy","layoffs":null,"summary":"Everads Therapy has announced a milestone achievement within its collaboration with a global pharmaceutical company. The company has granted exclusivity to the pharmaceutical company for utilizing its suprachoroidal delivery technology for specific ocular targets. In exchange, Everads will receive a milestone payment. The company retains the right to continue using and licensing its technologies for other therapies. The major pharmaceutical companys payment for exclusivity demonstrates the potential of Everads drug delivery technology. Everads is optimistic that the collaboration will lead to a commercial license. Everads Therapy is an ophthalmology-focused life-sciences company developing a revolutionary delivery system for suprachoroidal delivery of injectable therapies.","partners":["global pharmaceutical company"],"customers":null,"investors":null,"confidence":8,"key_topics":["retina treatment delivery technologies","suprachoroidal delivery technology","milestone achievement","collaboration","commercial license"],"date_of_event":"August 18, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"3YYjEhUGYhmGyAwV0Dk70gTQJs5MQoAeEEC0YxN5TISepQm296ocVU","news_summary":"Global Pharma Company Exercises Rights for Exclusive Use of Everads Drug Delivery Technology in Specific Retinal Targets","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"489e01bc-68ef-44c5-8397-1c7cf1398d49","date":"Mar 18, 2020","link":"https://en.globes.co.il/en/article-everads-therapy-wins-retina-injection-commercialization-deal-1001322368","source":"en.globes.co.il","visible":1,"analysis":{"tags":"Partnership, Medical Device, Ophthalmology","company":"Everads Therapy","layoffs":"N/A","summary":"Israeli medical company Everads Therapy has signed a commercialisation option agreement for its device that injects drugs into the back part of the eye. The device is aimed at treating retinal diseases such as dry AMD, wet AMD and other diabetic degenerative retinal diseases. The other company involved in the agreement, which markets drugs for ophthalmological diseases, was not named. The deal could potentially be worth billions of dollars. Everads will receive an upfront fee and payments for milestones, as well as a proportion of the other companys revenue if the product is integrated with their drug and reaches the market.","partners":"Unnamed drug developer","customers":"N/A","investors":"N/A","confidence":9,"key_topics":"Drug Injection Device, Ophthalmological Diseases, Commercialization Agreement","date_of_event":"March 18, 2020","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Partners","acquisition_amount":"N/A","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"EUanrYsjhGzElFYPJHpHELWzrtWt4IZpHC9mEBLp8dY9quNJIZajy6","news_summary":"Everads Therapy wins retina commercialization option deal","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"2aff8ded-4a78-4eaf-91f8-a61c196b984f","date":"Mar 12, 2020","link":"https://www.prnewswire.com/news-releases/everads-therapy-enters-into-option-agreement-with-global-pharma-company-to-license-everads-suprachoroidal-delivery-system-for-retinal-disease-therapies-301021829.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"pharmaceutical, retinal treatment delivery technologies","company":"Everads Therapy","layoffs":null,"summary":"Everads Therapy has signed an option agreement with a large global pharmaceutical company to evaluate its suprachoroidal delivery system. This is Everads first commercial agreement and supports the potential of its technology to improve retinal disease treatment options. The agreement grants the pharma company an exclusive option to enter into a license agreement for the use of Everads delivery system. The company believes its delivery system overcomes technical challenges and may provide superior outcomes compared to current injection methods. The goal is to improve the treatment of macular disease. Everads Therapy is a life sciences company operating within the RAD Biomed incubator in Tel Aviv, Israel.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["retinal treatment delivery technologies","suprachoroidal delivery system","commercial agreement","potential benefit","macular disease"],"date_of_event":"March 12, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"OCp2aiia3T7BNrIy8e5NVyjr7SDXvtOLmtkbxrTFex5YDmFRRqlRoj","news_summary":"Everads Therapy Enters Into Option Agreement With Global Pharma Company to License Everads' Suprachoroidal Delivery System for Retinal Disease Therapies","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":6,"techcommunityinvolvement":null,"mediagallery":[{"id":"nouNcI9sUCRrbGgTIE6mHAjaA4yDSeMt36JrfAzQGt2VwSDM7OY5J8","timestamp":"2022-11-22 20:11:37.000000","resources_type":1,"resources_title":"","resources_file_name":"$hlXN2JAgIH8xWv4VoxIZbVnG5Sa41wUE0chIqupYgJQnRGBWCbZxuq","alt":"","cleanBucketUrl":"https://storage.googleapis.com/clean-finder-353810","imageurl":"https://storage.googleapis.com/clean-finder-353810/$hlXN2JAgIH8xWv4VoxIZbVnG5Sa41wUE0chIqupYgJQnRGBWCbZxuq","url":"https://storage.googleapis.com/clean-finder-353810/$hlXN2JAgIH8xWv4VoxIZbVnG5Sa41wUE0chIqupYgJQnRGBWCbZxuq"}],"tags":["cell-therapy","ophthalmology","medical-devices","clinics","hospitals","biotechnology","doctors","drug-delivery","medical-technologies","eye-diseases","minimally-invasive","nanotechnology"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"technologysuccessstory":[{"date":"2017-01-01","name":"Non Invasive Pterygium Excision And Peeling","tags":["non-invasive","ophthalmology","medical-devices"],"category":"Medical Devices","tto_logo":"/image_cloud/tel-hashomer_tto_logo_5471b6e8-b5d5-11e8-8a10-c14be16af9ea","university_logo":"/image_cloud/tel-hashomer_institution_logo_5471b6e8-b5d5-11e8-8a10-c14be16af9ea"}],"usecases":[],"businessmodels":["B2B"],"productstage":"R&D","products":["Everads Delivery System"],"geomarkets":["Global"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":2,"lastfunding":"$1M","totalrounds":1,"fundingstage":"Seed","totalfunding":"$1M","publicinvestors":2,"lastpublicfunding":1000000,"totalpublicrounds":1,"totalpublicfunding":1000000},"team":[{"name":"Moshe  Weinstein","email":"mweinstein@everads-therapy.com","phone":"","gender":"Male","userid":"qyxFT6oPZEpWxmJNflsTHrlbLW4qQynY7gm8IuJi7hu5gfNEuezBvo","bounced":false,"claimed":null,"founder":0,"urlname":"moshe-weinstein","visible":1,"memberid":"zzhYOe6D95G4JUwrr4bYr8c8ZXwGc7xpowYZacwGjFgRrKzUBxmTM8","position":"Executive Chairman & CEO","last_name":"Weinstein","claimtoken":"1cHCCcQ90NxKd6QQneXjhjd6L7tsmKSB64fXvdGf6IHNC5mqFXFaSG","first_name":"Moshe ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/mosheweinstein/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2022-11-22 20:06:09.000000","initials":"MW","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Dr. Ifat Sher","email":"isher@everads-therapy.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4OS27JYJDA","bounced":true,"claimed":0,"founder":1,"urlname":"dr-ifat-sher","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDglO-wvQsM","position":"Co-founder & CSO","last_name":"Sher","claimtoken":"yucuznh2WcPeqBgF7kied2kLaLo9PX5ayUt9waV0nPmq1C9Ap53g0E","first_name":"Dr. Ifat","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":1,"additionalemail":"ifat@everads-therapy.com","claimedemaildate":"2022-11-22 20:04:30.000000","initials":"DS","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Dr. Ygal Rotenstreich","email":"yrotenstreich@everads-therapy.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4NSlxbUKDA","bounced":true,"claimed":0,"founder":1,"urlname":"dr-ygal-rotenstreich","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg1OaVywsM","position":"Co-founder & Medical Director","last_name":"Rotenstreich","claimtoken":"aa13470c7e8dc8a416cbfd4153f244bc401956a60006e7528d72bb3920311810","first_name":"Dr. Ygal","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":1,"additionalemail":"ygal@everads-therapy.com","claimedemaildate":"2020-12-01 09:20:42.000000","initials":"DR","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"David Daily","email":"ddaily@everads-therapy.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4NSMr8cIDA","bounced":true,"claimed":0,"founder":1,"urlname":"david-daily","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDglOHaiwoM","position":"Co-founder & R&D Director","last_name":"Daily","claimtoken":"CIemNWhPG42izMbcUrZKT456qTjQ04sgzHZJognAMLzkx0QIFSR9Ef","first_name":"David","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/dailydavid/","unsubscribed":false,"is_activeuser":1,"additionalemail":"david@everads-therapy.com","claimedemaildate":"2022-11-22 20:04:08.000000","initials":"DD","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Hagay Drori","email":"hdrori@everads-therapy.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4NbwxfQJDA","bounced":false,"claimed":1,"founder":0,"urlname":"hagay-drori-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg5LmFlgoM","position":"COO","last_name":"Drori","claimtoken":"1bf90d416eadd6a0d7ac7140b5537d2098b3e84f7daa8f74bf33516a8f5b0db7","first_name":"Hagay","picturekey":"$A2dyP3dBh14TtUwy5xkvRb4kTs7DLWNw9ymdWN7nsEfZqX1gL8yUsX","claimeddate":"2020-03-19","linkedinurl":"https://www.linkedin.com/in/hagay-drori-7327642/","unsubscribed":false,"is_activeuser":1,"additionalemail":"hagaydrori@gmail.com","claimedemaildate":"2020-03-19 15:43:31.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$A2dyP3dBh14TtUwy5xkvRb4kTs7DLWNw9ymdWN7nsEfZqX1gL8yUsX","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoPW8rMQKDA","fullname":"Lena Rogovina"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAwN25h58KDA","fullname":"Vered Waxman"},"biverifydate":"2020-03-31T00:00:00.000Z","crunchbaseid":"everads-therapy","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Yotam Maman","creator_email":"yotamm1988@gmail.com","createdate":"2019-05-30T00:00:00.000Z","biverification":"Vered Waxman","sectorverification":"Lena Rogovina","affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODU5ZiCCgw","date":"Jan 2017","amount":"$1M","source":"Rasham Ha-havarot- Directors Update + portfolio of Rad BioMed + confirmed with their COO","eventtype":"FundingRoundEvent","investment":[{"name":"EU Horizon 2020","type":"Other","amount":0,"hidden":false,"country":"Belgium","fullurl":"/company_page/eu-horizon-2020","logokey":"$Y11JsXnB1FT2S0h1lyXUQMAhH6bM0g2tSIdWQAjTFxivAoweBwRj4g","tagline":"","urlname":"/company_page/eu-horizon-2020","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE7vSzCgw","fundingtype":"Other","leadpartner":null,"investmentid":"46d9b921-00a4-44cb-b2ce-da68b0c1a20f","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Y11JsXnB1FT2S0h1lyXUQMAhH6bM0g2tSIdWQAjTFxivAoweBwRj4g","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"RAD BioMed","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/radbiomed","logokey":"$8Q5Rwt22LKpRes13ZNTxXwFNiOfEKKujTG6u7PIRBDQr1KJWlllXfv","tagline":null,"urlname":"/investor_page/radbiomed","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgKOh2oAKDA","fundingtype":"Incubator","leadpartner":null,"investmentid":"df23edba-e4bd-4f93-bce3-15c2ad75a063","fundingsubtype":"Incubator","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8Q5Rwt22LKpRes13ZNTxXwFNiOfEKKujTG6u7PIRBDQr1KJWlllXfv","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":1000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"5DdL7hzhpVQvrStNvwuOk7q2Q5QK6JIUAxypF74N6FxfEDbdbwpd0n","hub":"Arc Innovation Center","date":"","batch":"","amount":"Undisclosed","hub_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Nzf9a0IDA","source":"","enddate":"","hub_type":"Corporate Accelerator","eventtype":"GraduationEvent","hub_hidden":false,"investment":[],"hub_fullurl":"/program_page/arc-innovation-center","hub_logokey":"$h4kVs9Y8FIw1PlL9peLoiBUHlwkeM0hVe5lCktvnAuF1BF3VW20V0c","hub_urlname":"/program_page/arc-innovation-center","eventvisibility":null,"amountvisibility":null,"fundingvisibility":null,"style":"","hiddenCompanyTooltip":"","hub_logourl":"https://storage.googleapis.com/clean-finder-353810/$h4kVs9Y8FIw1PlL9peLoiBUHlwkeM0hVe5lCktvnAuF1BF3VW20V0c","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"1/2017","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Everads Therapy","logourl":"https://storage.googleapis.com/clean-finder-353810/$1DsWac0keu92mItKvilb2Avyh84BvwB21U59qkHMpgPmJBVeiXrSRn","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$1DsWac0keu92mItKvilb2Avyh84BvwB21U59qkHMpgPmJBVeiXrSRn","seoabout":"Everads Therapy is an early-stage life sciences company developing retinal treatment delivery technologies. The companys delivery system aims to improve th...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":5,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Medical Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Treatment & Therapeutics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drug Delivery","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","classificationName":"sectorclassification"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA>Medical Treatment & Therapeutics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drug Delivery#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA/Medical Treatment & Therapeutics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drug Delivery#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Medical Devices","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices","children":[{"title":"Medical Treatment & Therapeutics","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices>Medical Treatment & Therapeutics"}]},{"title":"Pharma & Medical Biotechnology","key":"0-0-1","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drug Delivery","key":"0-0-1-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drug Delivery"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Healthcare","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Providers","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Providers"}]},{"title":"Life Sciences","key":"0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-1-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Medical Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Treatment & Therapeutics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drug Delivery","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Medical Devices","Medical Treatment & Therapeutics","Pharma & Medical Biotechnology","Drug Delivery"],"coreTechnology":[],"targetCustomer":["Healthcare & Life Sciences","Healthcare","Providers","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODU5ZiCCgw","date":"Jan 2017","amount":"$1M","source":"Rasham Ha-havarot- Directors Update + portfolio of Rad BioMed + confirmed with their COO","eventtype":"FundingRoundEvent","investment":[{"name":"EU Horizon 2020","type":"Other","amount":0,"hidden":false,"country":"Belgium","fullurl":"/company_page/eu-horizon-2020","logokey":"$Y11JsXnB1FT2S0h1lyXUQMAhH6bM0g2tSIdWQAjTFxivAoweBwRj4g","tagline":"","urlname":"/company_page/eu-horizon-2020","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE7vSzCgw","fundingtype":"Other","leadpartner":null,"investmentid":"46d9b921-00a4-44cb-b2ce-da68b0c1a20f","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Y11JsXnB1FT2S0h1lyXUQMAhH6bM0g2tSIdWQAjTFxivAoweBwRj4g","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"RAD BioMed","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/radbiomed","logokey":"$8Q5Rwt22LKpRes13ZNTxXwFNiOfEKKujTG6u7PIRBDQr1KJWlllXfv","tagline":null,"urlname":"/investor_page/radbiomed","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgKOh2oAKDA","fundingtype":"Incubator","leadpartner":null,"investmentid":"df23edba-e4bd-4f93-bce3-15c2ad75a063","fundingsubtype":"Incubator","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8Q5Rwt22LKpRes13ZNTxXwFNiOfEKKujTG6u7PIRBDQr1KJWlllXfv","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":1000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}